These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22156656)

  • 1. Pilot study of a pediatric metronomic 4-drug regimen.
    André N; Abed S; Orbach D; Alla CA; Padovani L; Pasquier E; Gentet JC; Verschuur A
    Oncotarget; 2011 Dec; 2(12):960-5. PubMed ID: 22156656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Children treated with metronomic chemotherapy in a low-income country: METRO-MALI-01.
    Fousseyni T; Diawara M; Pasquier E; André N
    J Pediatr Hematol Oncol; 2011 Jan; 33(1):31-4. PubMed ID: 21164360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study.
    André N; Rome A; Coze C; Padovani L; Pasquier E; Camoin L; Gentet JC
    Clin Ther; 2008 Jul; 30(7):1336-40. PubMed ID: 18691994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary evaluation of children treated with metronomic chemotherapy and valproic acid in a low-income country: Metro-Mali-02.
    Traore F; Togo B; Pasquier E; Dembélé A; André N
    Indian J Cancer; 2013; 50(3):250-3. PubMed ID: 24061467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors.
    Stempak D; Gammon J; Halton J; Moghrabi A; Koren G; Baruchel S
    J Pediatr Hematol Oncol; 2006 Nov; 28(11):720-8. PubMed ID: 17114958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.
    Robison NJ; Campigotto F; Chi SN; Manley PE; Turner CD; Zimmerman MA; Chordas CA; Werger AM; Allen JC; Goldman S; Rubin JB; Isakoff MS; Pan WJ; Khatib ZA; Comito MA; Bendel AE; Pietrantonio JB; Kondrat L; Hubbs SM; Neuberg DS; Kieran MW
    Pediatr Blood Cancer; 2014 Apr; 61(4):636-42. PubMed ID: 24123865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors.
    Qayed M; Cash T; Tighiouart M; MacDonald TJ; Goldsmith KC; Tanos R; Kean L; Watkins B; Suessmuth Y; Wetmore C; Katzenstein HM
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28134. PubMed ID: 31876107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893.
    Felgenhauer JL; Nieder ML; Krailo MD; Bernstein ML; Henry DW; Malkin D; Baruchel S; Chuba PJ; Sailer SL; Brown K; Ranganathan S; Marina N
    Pediatr Blood Cancer; 2013 Mar; 60(3):409-14. PubMed ID: 23065953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of high-dose celecoxib and metronomic 'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma.
    El Bary NA; Hashem T; Metwally H; Ghany AA; El Mageed HA
    Hematol Oncol Stem Cell Ther; 2010; 3(1):13-8. PubMed ID: 20231809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer.
    Khan OA; Blann AD; Payne MJ; Middleton MR; Protheroe AS; Talbot DC; Taylor M; Kirichek O; Han C; Patil M; Harris AL
    Br J Cancer; 2011 Jun; 104(12):1822-7. PubMed ID: 21587257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metro-SMHOP 01: Metronomics combination with cyclophosphamide-etoposide and valproic acid for refractory and relapsing pediatric malignancies.
    El Kababri M; Benmiloud S; Cherkaoui S; El Houdzi J; Maani K; Ansari N; Khoubila N; Kili A; El Khorassani M; Madani A; Tazi MA; Ahid S; Hessissen L; Quessar A; Harif M; Khattab M; André N
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28508. PubMed ID: 32658380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium.
    Pasqualini C; Rubino J; Brard C; Cassard L; André N; Rondof W; Scoazec JY; Marchais A; Nebchi S; Boselli L; Grivel J; Aerts I; Thebaud E; Paoletti X; Minard-Colin V; Vassal G; Geoerger B
    Eur J Cancer; 2021 Jun; 150():53-62. PubMed ID: 33892407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metronomic chemotherapy in advanced oral cancers.
    Patil V; Noronha V; D'cruz AK; Banavali SD; Prabhash K
    J Cancer Res Ther; 2012 Jan; 8 Suppl 1():S106-10. PubMed ID: 22322727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.
    Berthold F; Hömberg M; Proleskovskaya I; Mazanek P; Belogurova M; Ernst A; Sterba J
    Pediatr Hematol Oncol; 2017 Aug; 34(5):308-319. PubMed ID: 29148865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic Four-Drug Regimen Has Anti-tumor Activity in Pediatric Low-Grade Glioma; The Results of a Phase II Clinical Trial.
    Verschuur A; Heng-Maillard MA; Dory-Lautrec P; Truillet R; Jouve E; Chastagner P; Leblond P; Aerts I; Honoré S; Entz-Werle N; Sirvent N; Gentet JC; Corradini N; André N
    Front Pharmacol; 2018; 9():00950. PubMed ID: 30319400
    [No Abstract]   [Full Text] [Related]  

  • 16. Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience.
    Zapletalova D; André N; Deak L; Kyr M; Bajciova V; Mudry P; Dubska L; Demlova R; Pavelka Z; Zitterbart K; Skotakova J; Husek K; Martincekova A; Mazanek P; Kepak T; Doubek M; Kutnikova L; Valik D; Sterba J
    Oncology; 2012; 82(5):249-60. PubMed ID: 22538363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study.
    Sterba J; Valik D; Mudry P; Kepak T; Pavelka Z; Bajciova V; Zitterbart K; Kadlecova V; Mazanek P
    Onkologie; 2006 Jul; 29(7):308-13. PubMed ID: 16874014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metronomic Maintenance With Weekly Vinblastine After Induction With Bevacizumab-Irinotecan in Children With Low-grade Glioma Prevents Early Relapse.
    Roux C; Revon-Rivière G; Gentet JC; Verschuur A; Scavarda D; Saultier P; Appay R; Padovani L; André N
    J Pediatr Hematol Oncol; 2021 Jul; 43(5):e630-e634. PubMed ID: 33235152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.
    Toulmonde M; Pulido M; Ray-Coquard I; Andre T; Isambert N; Chevreau C; Penel N; Bompas E; Saada E; Bertucci F; Lebbe C; Le Cesne A; Soulie P; Piperno-Neumann S; Sweet S; Cecchi F; Hembrough T; Bellera C; Kind M; Crombe A; Lucchesi C; Le Loarer F; Blay JY; Italiano A
    Lancet Oncol; 2019 Sep; 20(9):1263-1272. PubMed ID: 31331699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial.
    Pramanik R; Agarwala S; Gupta YK; Thulkar S; Vishnubhatla S; Batra A; Dhawan D; Bakhshi S
    JAMA Oncol; 2017 Sep; 3(9):1222-1227. PubMed ID: 28384657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.